[123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration.
Identifieur interne : 003E30 ( PubMed/Checkpoint ); précédent : 003E29; suivant : 003E31[123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration.
Auteurs : W. Pirker [Autriche] ; S. Asenbaum ; G. Bencsits ; D. Prayer ; W. Gerschlager ; L. Deecke ; T. BrückeSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2000.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Basal Ganglia (radionuclide imaging), Case-Control Studies, Cerebral Cortex (radionuclide imaging), Cocaine (analogs & derivatives), Cocaine (diagnostic use), Diagnosis, Differential, Female, Humans, Image Processing, Computer-Assisted, Iodine Radioisotopes (diagnostic use), Male, Middle Aged, Multiple System Atrophy (radionuclide imaging), Neurodegenerative Diseases (radionuclide imaging), Parkinson Disease (radionuclide imaging), Predictive Value of Tests, Radiopharmaceuticals (diagnostic use), Supranuclear Palsy, Progressive (radionuclide imaging), Tomography, Emission-Computed, Single-Photon (methods).
- MESH :
- chemical , analogs & derivatives : Cocaine.
- chemical , diagnostic use : Cocaine, Iodine Radioisotopes, Radiopharmaceuticals.
- methods : Tomography, Emission-Computed, Single-Photon.
- radionuclide imaging : Basal Ganglia, Cerebral Cortex, Multiple System Atrophy, Neurodegenerative Diseases, Parkinson Disease, Supranuclear Palsy, Progressive.
- Adult, Aged, Aged, 80 and over, Case-Control Studies, Diagnosis, Differential, Female, Humans, Image Processing, Computer-Assisted, Male, Middle Aged, Predictive Value of Tests.
Abstract
Differentiation between Parkinson's disease (PD) and other neurodegenerative disorders with parkinsonian features, such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD), is difficult on clinical grounds. We studied the pattern of dopaminergic degeneration in 18 patients with probable MSA, 8 patients with PSP, 4 patients with CBD, 48 patients with PD and a similar degree of disability, and 14 control subjects performing single photon emission computed tomography (SPECT) 20 hours after injection of [123I]beta-CIT. Overall striatal binding was significantly reduced in MSA (-51% of normal mean), PSP (-60%), CBD (-35%), and PD (-58%), without overlap with control values. Asymmetry of striatal beta-CIT binding was significantly increased in patients with CBD and PD, as compared with control subjects. Although asymmetry seemed to be less pronounced in MSA and PSP than in PD, this was not statistically significant. Putamen-caudate nucleus ratios in patients with PD, MSA, and PSP, but not with CBD, were significantly reduced, as compared with control subjects. In conclusion, [123I]beta-CIT SPECT reliably enables the visualization of the presynaptic dopaminergic lesion in patients with MSA, PSP, and CBD. In most patients, however, it does not seem to be possible to differentiate these disorders from PD with this method.
PubMed: 11104200
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:11104200Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration.</title><author><name sortKey="Pirker, W" sort="Pirker, W" uniqKey="Pirker W" first="W" last="Pirker">W. Pirker</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Neurology, University of Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Clinical Neurology, University of Vienna</wicri:regionArea><wicri:noRegion>University of Vienna</wicri:noRegion></affiliation></author><author><name sortKey="Asenbaum, S" sort="Asenbaum, S" uniqKey="Asenbaum S" first="S" last="Asenbaum">S. Asenbaum</name></author><author><name sortKey="Bencsits, G" sort="Bencsits, G" uniqKey="Bencsits G" first="G" last="Bencsits">G. Bencsits</name></author><author><name sortKey="Prayer, D" sort="Prayer, D" uniqKey="Prayer D" first="D" last="Prayer">D. Prayer</name></author><author><name sortKey="Gerschlager, W" sort="Gerschlager, W" uniqKey="Gerschlager W" first="W" last="Gerschlager">W. Gerschlager</name></author><author><name sortKey="Deecke, L" sort="Deecke, L" uniqKey="Deecke L" first="L" last="Deecke">L. Deecke</name></author><author><name sortKey="Brucke, T" sort="Brucke, T" uniqKey="Brucke T" first="T" last="Brücke">T. Brücke</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2000">2000</date><idno type="RBID">pubmed:11104200</idno><idno type="pmid">11104200</idno><idno type="wicri:Area/PubMed/Corpus">003E65</idno><idno type="wicri:Area/PubMed/Curation">003E65</idno><idno type="wicri:Area/PubMed/Checkpoint">003E30</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration.</title><author><name sortKey="Pirker, W" sort="Pirker, W" uniqKey="Pirker W" first="W" last="Pirker">W. Pirker</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Neurology, University of Vienna, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Clinical Neurology, University of Vienna</wicri:regionArea><wicri:noRegion>University of Vienna</wicri:noRegion></affiliation></author><author><name sortKey="Asenbaum, S" sort="Asenbaum, S" uniqKey="Asenbaum S" first="S" last="Asenbaum">S. Asenbaum</name></author><author><name sortKey="Bencsits, G" sort="Bencsits, G" uniqKey="Bencsits G" first="G" last="Bencsits">G. Bencsits</name></author><author><name sortKey="Prayer, D" sort="Prayer, D" uniqKey="Prayer D" first="D" last="Prayer">D. Prayer</name></author><author><name sortKey="Gerschlager, W" sort="Gerschlager, W" uniqKey="Gerschlager W" first="W" last="Gerschlager">W. Gerschlager</name></author><author><name sortKey="Deecke, L" sort="Deecke, L" uniqKey="Deecke L" first="L" last="Deecke">L. Deecke</name></author><author><name sortKey="Brucke, T" sort="Brucke, T" uniqKey="Brucke T" first="T" last="Brücke">T. Brücke</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2000" type="published">2000</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Basal Ganglia (radionuclide imaging)</term><term>Case-Control Studies</term><term>Cerebral Cortex (radionuclide imaging)</term><term>Cocaine (analogs & derivatives)</term><term>Cocaine (diagnostic use)</term><term>Diagnosis, Differential</term><term>Female</term><term>Humans</term><term>Image Processing, Computer-Assisted</term><term>Iodine Radioisotopes (diagnostic use)</term><term>Male</term><term>Middle Aged</term><term>Multiple System Atrophy (radionuclide imaging)</term><term>Neurodegenerative Diseases (radionuclide imaging)</term><term>Parkinson Disease (radionuclide imaging)</term><term>Predictive Value of Tests</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Supranuclear Palsy, Progressive (radionuclide imaging)</term><term>Tomography, Emission-Computed, Single-Photon (methods)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Cocaine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Cocaine</term><term>Iodine Radioisotopes</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Tomography, Emission-Computed, Single-Photon</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Basal Ganglia</term><term>Cerebral Cortex</term><term>Multiple System Atrophy</term><term>Neurodegenerative Diseases</term><term>Parkinson Disease</term><term>Supranuclear Palsy, Progressive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Diagnosis, Differential</term><term>Female</term><term>Humans</term><term>Image Processing, Computer-Assisted</term><term>Male</term><term>Middle Aged</term><term>Predictive Value of Tests</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Differentiation between Parkinson's disease (PD) and other neurodegenerative disorders with parkinsonian features, such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD), is difficult on clinical grounds. We studied the pattern of dopaminergic degeneration in 18 patients with probable MSA, 8 patients with PSP, 4 patients with CBD, 48 patients with PD and a similar degree of disability, and 14 control subjects performing single photon emission computed tomography (SPECT) 20 hours after injection of [123I]beta-CIT. Overall striatal binding was significantly reduced in MSA (-51% of normal mean), PSP (-60%), CBD (-35%), and PD (-58%), without overlap with control values. Asymmetry of striatal beta-CIT binding was significantly increased in patients with CBD and PD, as compared with control subjects. Although asymmetry seemed to be less pronounced in MSA and PSP than in PD, this was not statistically significant. Putamen-caudate nucleus ratios in patients with PD, MSA, and PSP, but not with CBD, were significantly reduced, as compared with control subjects. In conclusion, [123I]beta-CIT SPECT reliably enables the visualization of the presynaptic dopaminergic lesion in patients with MSA, PSP, and CBD. In most patients, however, it does not seem to be possible to differentiate these disorders from PD with this method.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">11104200</PMID><DateCreated><Year>2001</Year><Month>03</Month><Day>07</Day></DateCreated><DateCompleted><Year>2001</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>6</Issue><PubDate><Year>2000</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>[123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration.</ArticleTitle><Pagination><MedlinePgn>1158-67</MedlinePgn></Pagination><Abstract><AbstractText>Differentiation between Parkinson's disease (PD) and other neurodegenerative disorders with parkinsonian features, such as multiple system atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD), is difficult on clinical grounds. We studied the pattern of dopaminergic degeneration in 18 patients with probable MSA, 8 patients with PSP, 4 patients with CBD, 48 patients with PD and a similar degree of disability, and 14 control subjects performing single photon emission computed tomography (SPECT) 20 hours after injection of [123I]beta-CIT. Overall striatal binding was significantly reduced in MSA (-51% of normal mean), PSP (-60%), CBD (-35%), and PD (-58%), without overlap with control values. Asymmetry of striatal beta-CIT binding was significantly increased in patients with CBD and PD, as compared with control subjects. Although asymmetry seemed to be less pronounced in MSA and PSP than in PD, this was not statistically significant. Putamen-caudate nucleus ratios in patients with PD, MSA, and PSP, but not with CBD, were significantly reduced, as compared with control subjects. In conclusion, [123I]beta-CIT SPECT reliably enables the visualization of the presynaptic dopaminergic lesion in patients with MSA, PSP, and CBD. In most patients, however, it does not seem to be possible to differentiate these disorders from PD with this method.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pirker</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Clinical Neurology, University of Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asenbaum</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bencsits</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Prayer</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gerschlager</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Deecke</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Brücke</LastName><ForeName>T</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>UNITED STATES</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007457">Iodine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>133647-95-7</RegistryNumber><NameOfSubstance UI="C069723">RTI 55</NameOfSubstance></Chemical><Chemical><RegistryNumber>I5Y540LHVR</RegistryNumber><NameOfSubstance UI="D003042">Cocaine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001479">Basal Ganglia</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002540">Cerebral Cortex</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003042">Cocaine</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000031">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D003937">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007091">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007457">Iodine Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019578">Multiple System Atrophy</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019636">Neurodegenerative Diseases</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011237">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D019275">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000176">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013494">Supranuclear Palsy, Progressive</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000531">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D015899">Tomography, Emission-Computed, Single-Photon</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>12</Month><Day>5</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>6</Month><Day>2</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>12</Month><Day>5</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11104200</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Autriche</li></country></list><tree><noCountry><name sortKey="Asenbaum, S" sort="Asenbaum, S" uniqKey="Asenbaum S" first="S" last="Asenbaum">S. Asenbaum</name><name sortKey="Bencsits, G" sort="Bencsits, G" uniqKey="Bencsits G" first="G" last="Bencsits">G. Bencsits</name><name sortKey="Brucke, T" sort="Brucke, T" uniqKey="Brucke T" first="T" last="Brücke">T. Brücke</name><name sortKey="Deecke, L" sort="Deecke, L" uniqKey="Deecke L" first="L" last="Deecke">L. Deecke</name><name sortKey="Gerschlager, W" sort="Gerschlager, W" uniqKey="Gerschlager W" first="W" last="Gerschlager">W. Gerschlager</name><name sortKey="Prayer, D" sort="Prayer, D" uniqKey="Prayer D" first="D" last="Prayer">D. Prayer</name></noCountry><country name="Autriche"><noRegion><name sortKey="Pirker, W" sort="Pirker, W" uniqKey="Pirker W" first="W" last="Pirker">W. Pirker</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E30 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 003E30 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:11104200
|texte= [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:11104200" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |